401
edits
Heart Failure: Difference between revisions
Jump to navigation
Jump to search
→Management
| Line 216: | Line 216: | ||
== Management == | == Management == | ||
The management of HF involves both pharmacological and non-pharmacological treatment. The emphasis is on the reduction in mortality and morbidity, prevention of the progression of HF, and the treatment of (non-)cardiovascular co-morbidities. Myocardial infarction (MI) is the most important cause of HF. Management of coronary disease is crucial in these patients, as revascularization of the myocardium will increase exercise capacity and survival. | The management of HF involves both pharmacological and non-pharmacological treatment. The emphasis is on the reduction in mortality and morbidity, prevention of the progression of HF, and the treatment of (non-)cardiovascular co-morbidities. Myocardial infarction (MI) is the most important cause of HF. Management of coronary disease is crucial in these patients, as revascularization of the myocardium will increase exercise capacity and survival. | ||
Research shows that good adherence to medication is associated with a decrease in risk of death. | Research shows that good adherence to medication is associated with a decrease in risk of death. <cite>Granger</cite> Nevertheless, the percentage of HF patients adhering to prescribed pharmacological and non-pharmacological treatment is as low as 20-60 % according to the literature <cite>Evangelista</cite> <cite>VanDerWal</cite>. | ||
Treatment of diastolic- and systolic HF does not differ (vd wall). Non-pharmalogical treatment can be applied in every patient. | Treatment of diastolic- and systolic HF does not differ (vd wall). Non-pharmalogical treatment can be applied in every patient. | ||
==== Non-pharmacological treatment ==== | ==== Non-pharmacological treatment ==== | ||